Cargando…

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection

BACKGROUND: GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator (class I) that can inhibit HBV replication by interfering with the assembly and disassembly of HBV nucleocapsid. Here, we evaluated its antiviral activity, pharmacokinetics, and tolerability in a double-blind, ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hong, Wang, Fengjiao, Zhu, Xiaoxue, Chen, Yunfu, Chen, Hong, Li, Xiaojiao, Wu, Min, Li, Cuiyun, Liu, Jingrui, Zhang, Yingjun, Ding, Yanhua, Niu, Junqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516514/ https://www.ncbi.nlm.nih.gov/pubmed/32649736 http://dx.doi.org/10.1093/cid/ciaa961

Ejemplares similares

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects
por: Li, Xiaojiao, et al.
Publicado: (2021)

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(®)) in Chinese healthy subjects
por: Zhang, Hong, et al.
Publicado: (2021)

Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives
por: Taverniti, Valerio, et al.
Publicado: (2022)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
por: Liu, Jingrui, et al.
Publicado: (2021)

Evans Blue Inhibits HBV Replication Through a Dual Antiviral Mechanism by Targeting Virus Binding and Capsid Assembly
por: Xiao, Yu, et al.
Publicado: (2019)

Targeting the HIV-1 and HBV Capsids, an EnCore
por: McFadden, William M., et al.
Publicado: (2023)

Pharmacokinetics of Anti-HBV Polyoxometalate in Rats
por: Wang, Juan, et al.
Publicado: (2014)

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial
por: Jia, Haiyan, et al.
Publicado: (2023)

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2018)

Pharmacomodulation of a ligand targeting the HBV capsid hydrophobic pocket
por: Briday, Mathilde, et al.
Publicado: (2022)

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
por: Zhang, Hong, et al.
Publicado: (2021)

Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy
por: Audsley, Jennifer, et al.
Publicado: (2016)

Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice
por: Ye, Lei, et al.
Publicado: (2017)

The Origin of Capsid-Derived Immune Complexes and Their Impact on HBV-Induced Liver Diseases
por: Zhang, Xiaonan, et al.
Publicado: (2022)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients
por: Hu, Zili, et al.
Publicado: (2022)

Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative
por: Wang, Kai, et al.
Publicado: (2018)

Antiviral therapy of chronic HBV infection in pregnancy
por: Nikolajuk-Stasiuk, Julita, et al.
Publicado: (2016)

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
por: Yu, Liang-He, et al.
Publicado: (2011)

HBV-Derived Synthetic Long Peptide Can Boost CD4(+) and CD8(+) T-Cell Responses in Chronic HBV Patients Ex Vivo
por: Dou, Yingying, et al.
Publicado: (2018)

Author Correction: Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice
por: Ye, Lei, et al.
Publicado: (2018)

IL28B Is Associated with Outcomes of Chronic HBV Infection
por: Shi, Xiaodong, et al.
Publicado: (2015)

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
por: Chen, Jian-Lin, et al.
Publicado: (2016)

Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment
por: Wang, Xiaomei, et al.
Publicado: (2021)

1248. Relationship Between ALT and New HBV Biomarkers in HBV/HIV Coinfected Persons Started on Antiviral Therapy
por: Rouster, Susan D, et al.
Publicado: (2022)

Editorial: Interferon and its antiviral effect in response to HBV infection
por: Song, Hongxiao, et al.
Publicado: (2023)

Glucocorticoids and Antivirals for HBV Reactivation in Onco-Hematologic Patients.
por: Marzano, Alfredo, et al.
Publicado: (2010)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment
por: Hu, Yue, et al.
Publicado: (2022)

Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection–Related Hepatocellular Carcinoma
por: Zhao, Li, et al.
Publicado: (2021)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
por: Zhang, Hong, et al.
Publicado: (2021)

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
por: Liu, Jian, et al.
Publicado: (2023)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
por: Zhang, Hong, et al.
Publicado: (2020)

Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC
por: You, Maojun, et al.
Publicado: (2023)

The Dual Role of an ESCRT-0 Component HGS in HBV Transcription and Naked Capsid Secretion
por: Chou, Shu-Fan, et al.
Publicado: (2015)

Increased Expression of miR-487b Is Associated With Poor Prognosis and Tumor Progression of HBV-Related Hepatocellular Carcinoma
por: Cao, Xiangang, et al.
Publicado: (2020)

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
por: Chen, Tianyan, et al.
Publicado: (2013)

The HBV Specially-Related Long Noncoding RNA HBV-SRL Involved in the Pathogenesis of Hepatocellular Carcinoma
por: Zhang, Cunzhen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_blfb68i4rjrggklfdjlgvvkg3l